Quick Comparison
| Category | Embody GLP-1 | Mochi Health |
|---|---|---|
| Model | One flat monthly fee, medication included | $79/mo membership + medication billed separately |
| Advertised entry price | $99/mo promotional rate (listed as “was $299”) — verified 7/9/2026 | Membership $79/mo + compounded semaglutide $99/mo (all doses) — verified 7/3/2026 |
| Compounded tirzepatide | Offered; promotional discounts advertised ($250 off) | $199/mo (all doses) + $79/mo membership |
| Brand-name option | Not the focus | Yes — Wegovy/Zepbound billed through insurance when covered |
| Medication types | Compounded semaglutide and tirzepatide (injections and oral gum), from U.S. 503A compounding pharmacies | Compounded and brand-name GLP-1 |
| Insurance | Not required, cash-pay | Optional — used for brand-name pathway |
| State availability | All US states except Mississippi and Louisiana (verified 7/9/2026) | Confirm at signup |
The Verdict
On verified cash price for compounded semaglutide, Embody’s advertised all-in rate ($99/mo promotional) is lower than Mochi’s combined cost (about $178/mo: $79 membership + $99 medication). But that’s only the right comparison if you want compounded medication and plan to pay cash.
Mochi wins on optionality. If you have insurance that may cover Wegovy or Zepbound, Mochi’s membership model is built to pursue that — and brand-name coverage, when it works, can beat any compounded cash price on out-of-pocket cost. Embody doesn’t compete on that path.
One honest caution on Embody’s pricing: the $99/mo figure is presented as a promotional rate against a $299 list price, with countdown-style urgency on the page. Confirm what your rate is after the promotional period — and what dose escalation does to it — before enrolling.
How Embody GLP-1 Works
Embody GLP-1 is a cash-pay telehealth program for compounded GLP-1 medication. Per its site (verified July 9, 2026): prescription and telemedicine visits are included in the monthly price, no insurance is required, pricing is the same at every dose, and medication ships from U.S.-based 503A compounding pharmacies. It offers compounded semaglutide and compounded tirzepatide in both injectable and oral-gum forms, and advertises no membership fee and cancel-anytime terms.
Embody is not available in Mississippi or Louisiana, where state rules restrict telehealth prescribing of weight-management medication.
Read the full Embody GLP-1 review or check Embody’s current pricing.
How Mochi Health Works
Mochi Health pairs a $79/month membership — covering visits with obesity-medicine clinicians — with medication billed separately. Compounded semaglutide runs $99/month and compounded tirzepatide $199/month at any dose (verified July 3, 2026), or Mochi can prescribe brand-name Wegovy/Zepbound billed through your insurance when coverage applies. That last path is Mochi’s real differentiator: if your plan covers a brand-name GLP-1, your total cost can drop below any cash program.
The watch-out is the reverse case: without insurance coverage, the membership fee stacks on top of medication cost every month, and the combined figure is what you should compare — not the medication price alone.
Read the full Mochi Health review or our deeper look at whether Mochi is worth it.
Who Should Choose Embody GLP-1?
- You want one predictable monthly number with medication and visits included
- You’re paying cash and want the lowest verified all-in entry price of the two
- You prefer a program with no membership fee and no dose-based price increases
- You’re not in Mississippi or Louisiana
Who Should Choose Mochi Health?
- You have insurance that might cover Wegovy or Zepbound, and want clinicians who will pursue it
- You want the option to move between compounded and brand-name medication
- You value obesity-medicine-focused care and don’t mind a membership fee for it
Safety note on compounded GLP-1 medications: Both programs prescribe compounded GLP-1 medications. Compounded medications are not the same as FDA-approved brand-name drugs: they are not reviewed by the FDA for safety, effectiveness, or quality before sale. Before starting either program, ask which pharmacy fills the prescription, whether it is properly licensed, and how dosing instructions are provided. No GLP-1 medication should be used without a prescription from a licensed clinician. GLP-1 medications are not appropriate for everyone — including, per FDA labeling for semaglutide and tirzepatide, people with a personal or family history of medullary thyroid carcinoma or MEN2 — and side effects can include nausea, vomiting, diarrhea, constipation, abdominal pain, and dehydration.
FAQ
Is Embody cheaper than Mochi?
For compounded semaglutide paid in cash, yes at current verified rates: Embody’s advertised $99/mo all-in (promotional, verified 7/9/2026) vs. Mochi’s ~$178/mo combined ($79 membership + $99 medication, verified 7/3/2026). If your insurance covers brand-name medication through Mochi, that math can flip.
Does either program offer brand-name Wegovy or Zepbound?
Mochi does, billed through insurance when coverage applies. Embody’s program is built around compounded semaglutide and tirzepatide.
Can either program guarantee a prescription?
No. In both programs, a licensed clinician reviews your health history and prescribes only when treatment is clinically appropriate. Any program promising a guaranteed prescription is a red flag.
What happens to Embody’s price after the promotion?
Embody lists $99/mo against a $299 list price. Its site states “same price, every dose,” but confirm the post-promotional rate directly with Embody before enrolling — promotional pricing was current as of July 9, 2026 and can change.
RangeYourself may earn a commission if you sign up through links on this page — see how we make money. Rankings and verdicts are based on verified pricing and program structure, never on commissions. Prices change frequently — always confirm current rates on each provider’s website before purchasing.
RangeYourself is reader-supported. We may earn a commission when you click on certain links — at no extra cost to you. Editorial recommendations are made independently. Last reviewed July 9, 2026.
